BRPI0818963A2 - Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo - Google Patents
Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduoInfo
- Publication number
- BRPI0818963A2 BRPI0818963A2 BRPI0818963A BRPI0818963A2 BR PI0818963 A2 BRPI0818963 A2 BR PI0818963A2 BR PI0818963 A BRPI0818963 A BR PI0818963A BR PI0818963 A2 BRPI0818963 A2 BR PI0818963A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- individual
- treat cancer
- molecule conjugate
- partner molecule
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99169307P | 2007-11-30 | 2007-11-30 | |
| PCT/US2008/084923 WO2009073533A2 (en) | 2007-11-30 | 2008-11-26 | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0818963A2 true BRPI0818963A2 (pt) | 2015-05-05 |
Family
ID=40427123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0818963 BRPI0818963A2 (pt) | 2007-11-30 | 2008-11-26 | Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110085970A1 (pt) |
| EP (1) | EP2224958A2 (pt) |
| JP (1) | JP2011505372A (pt) |
| KR (1) | KR20100093578A (pt) |
| CN (1) | CN101951959A (pt) |
| AR (1) | AR069747A1 (pt) |
| AU (1) | AU2008334063A1 (pt) |
| BR (1) | BRPI0818963A2 (pt) |
| CA (1) | CA2706926A1 (pt) |
| CL (1) | CL2008003526A1 (pt) |
| EA (1) | EA201000910A1 (pt) |
| IL (1) | IL205993A0 (pt) |
| MX (1) | MX2010005830A (pt) |
| TW (1) | TW200938224A (pt) |
| WO (1) | WO2009073533A2 (pt) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG170080A1 (en) | 2005-12-08 | 2011-04-29 | Medarex Inc | Human monoclonal antibodies to o8e |
| JP5211790B2 (ja) * | 2007-03-26 | 2013-06-12 | 住友化学株式会社 | Ｄｎａメチル化測定方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| PL2344478T3 (pl) | 2008-11-03 | 2018-02-28 | Syntarga B.V. | Analogi CC-1065 oraz ich koniugaty |
| AR077594A1 (es) | 2009-07-31 | 2011-09-07 | Organon Nv | Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t) |
| PT2542256T (pt) | 2010-03-04 | 2019-09-05 | Macrogenics Inc | Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PT2560645T (pt) | 2010-04-21 | 2016-10-24 | Syntarga Bv | Conjugados de análogos de cc-1065 e ligantes bifuncionais |
| TWI538918B (zh) | 2010-10-20 | 2016-06-21 | 財團法人工業技術研究院 | 人源化之單株抗體、其核苷酸序列與其用途 |
| WO2012145568A1 (en) | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| KR102049817B1 (ko) | 2011-08-01 | 2019-12-02 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| CN104244718A (zh) * | 2011-12-05 | 2014-12-24 | 伊格尼卡生物治疗公司 | 抗体-药物缀合物以及相关化合物、组合物和方法 |
| ES2745211T3 (es) | 2012-04-12 | 2020-02-28 | Univ Yale | Vehículos para la administración controlada de diferentes agentes farmacéuticos |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP2016505843A (ja) | 2012-12-19 | 2016-02-25 | アンプリミューン， インコーポレイテッド | Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法 |
| EP2954327A1 (en) | 2013-02-07 | 2015-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| AU2014244424A1 (en) * | 2013-03-14 | 2015-08-27 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| AU2014299561B2 (en) * | 2013-06-24 | 2017-06-08 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
| HRP20192174T1 (hr) | 2013-08-08 | 2020-03-06 | Cytune Pharma | Kombinirani farmaceutski pripravak |
| JP6845691B2 (ja) | 2013-11-01 | 2021-03-24 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 免疫療法のための調節粒子 |
| LT3092010T (lt) | 2014-01-10 | 2018-10-25 | Synthon Biopharmaceuticals B.V. | Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų |
| CN103981150B (zh) * | 2014-03-28 | 2016-06-01 | 苏州大学 | 抗人b7-h4单克隆抗体及其制备和应用 |
| SG11201610074YA (en) | 2014-06-06 | 2016-12-29 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| EP3169361B1 (en) | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP6943760B2 (ja) * | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
| CA2968357A1 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
| SMT202000579T1 (it) | 2014-11-21 | 2020-11-10 | Bristol Myers Squibb Co | Anticorpi comprendenti regioni costanti pesanti modificate |
| EA039219B1 (ru) | 2014-12-23 | 2021-12-20 | Бристол-Майерс Сквибб Компани | Антитела к tigit |
| MA53243A (fr) | 2015-04-17 | 2021-06-23 | Bristol Myers Squibb Co | Compositions comprenant une combinaison de ipilimumab et nivolumab |
| TWI870335B (zh) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| PE20181151A1 (es) | 2015-07-30 | 2018-07-17 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| JP7320944B2 (ja) | 2015-10-08 | 2023-08-04 | マクロジェニクス，インコーポレーテッド | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 |
| EP3377532B1 (en) | 2015-11-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| EP3423494A1 (en) | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| WO2017155981A1 (en) | 2016-03-07 | 2017-09-14 | Massachusetts Institute Of Technology | Protein-chaperoned t-cell vaccines |
| NZ747029A (en) | 2016-04-15 | 2025-05-02 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| DK3458053T3 (da) | 2016-05-20 | 2022-02-21 | Biohaven Therapeutics Ltd | Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling |
| JP6994223B2 (ja) * | 2016-07-26 | 2022-02-04 | 静岡県 | 抗ｂ７－ｈ４抗体 |
| BR112019002127A2 (pt) | 2016-08-03 | 2019-09-17 | Nextcure Inc | proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão |
| EP3512563A1 (en) | 2016-09-16 | 2019-07-24 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
| WO2018099539A1 (en) * | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
| AU2017367734B2 (en) | 2016-12-01 | 2025-01-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging |
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| MA50056A (fr) | 2017-03-31 | 2020-02-05 | Bristol Myers Squibb Co | Procédés de traitement de tumeur |
| EP3612567B1 (en) * | 2017-04-19 | 2024-09-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| SG10201913206RA (en) | 2017-05-25 | 2020-02-27 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant regions |
| MX2020002076A (es) | 2017-08-25 | 2020-03-24 | Five Prime Therapeutics Inc | Anticuerpos de b7-h4 y metodos para usarlos. |
| SG11202001479RA (en) * | 2017-08-31 | 2020-03-30 | Io Therapeutics Inc | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
| CN111247169A (zh) | 2017-10-15 | 2020-06-05 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
| CN108148137B (zh) * | 2017-12-29 | 2021-03-23 | 中国人民解放军第四军医大学 | 一种b7h4/1e10单克隆抗体及其应用 |
| ES2980171T3 (es) | 2018-01-23 | 2024-09-30 | Nextcure Inc | Anticuerpos B7-H4 y métodos de uso de los mismos |
| EP3753951A4 (en) * | 2018-02-11 | 2022-03-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF |
| EP3755720A1 (en) * | 2018-02-21 | 2020-12-30 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| WO2019169212A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| CN111886256B (zh) | 2018-03-23 | 2025-01-10 | 百时美施贵宝公司 | 抗mica和/或micb抗体及其用途 |
| EP3774911A1 (en) | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| MA53911A (fr) * | 2018-10-15 | 2022-01-19 | Five Prime Therapeutics Inc | Polythérapie contre le cancer |
| WO2020140070A1 (en) * | 2018-12-27 | 2020-07-02 | Gigagen, Inc. | Anti-b7-h4 binding proteins and methods of use thereof |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| BR112021024406A2 (pt) * | 2019-06-06 | 2022-04-19 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Conjugado anticorpo-fármaco anti-b7-h4 e uso medicinal do mesmo |
| EP3986460A2 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
| AU2020295012A1 (en) | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 or anti-PD-L1 antibody |
| WO2021108025A1 (en) | 2019-11-26 | 2021-06-03 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
| CN110981961B (zh) * | 2019-11-28 | 2022-07-29 | 青岛大学 | 一种特异结合癌细胞蛋白b7-h4的纳米抗体h6的序列和应用 |
| CN115087464B (zh) | 2019-12-13 | 2025-02-25 | 科优基因公司 | 新型白介素-15(il-15)融合蛋白及其用途 |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CA3168613A1 (en) | 2020-03-18 | 2021-09-23 | Genmab A/S | Antibodies binding to b7h4 |
| MX2022014191A (es) | 2020-05-13 | 2022-12-07 | Massachusetts Inst Technology | Composiciones de microdispositivos polimericos y su uso en la inmunoterapia de cancer. |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| KR20230013113A (ko) * | 2020-06-30 | 2023-01-26 | 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 | 항-b7h4 항체, 이중특이적 항체, 및 이의 용도 |
| JP2023530766A (ja) * | 2020-06-30 | 2023-07-19 | ハーバー・バイオメド・ユーエス・インコーポレイテッド | 二重特異性抗体及びその用途 |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| DK4267105T3 (da) | 2020-12-28 | 2025-05-19 | Bristol Myers Squibb Co | Antistofsammensætninger og fremgangsmåder til anvendelse deraf |
| US11964024B2 (en) | 2021-01-04 | 2024-04-23 | Mersana Therapeutics, Inc. | B7H4-targeted antibody-drug conjugates and methods of use thereof |
| US20240423972A1 (en) | 2021-02-01 | 2024-12-26 | Yale University | Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment |
| CA3207652A1 (en) | 2021-03-26 | 2022-09-29 | Stephanie Cornen | Cytokine anchors for nkp46-binding nk cell engager proteins |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| KR20240004949A (ko) | 2021-05-07 | 2024-01-11 | 젠맵 에이/에스 | B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| CN118159559A (zh) * | 2021-08-18 | 2024-06-07 | 和铂医药(上海)有限责任公司 | 一种抗b7-h4抗体及其制备方法和应用 |
| AU2023272488A1 (en) * | 2022-05-17 | 2024-11-28 | Mersana Therapeutics, Inc. | B7-h4-targeted antibody-drug conjugates for the treatment of cancer |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| WO2024040264A1 (en) | 2022-08-19 | 2024-02-22 | Massachusetts Institute Of Technology | Compositions and methods for targeting dendritic cell lectins |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| AU2023361162A1 (en) | 2022-10-11 | 2025-05-29 | Yale University | Compositions and methods of using cell-penetrating antibodies |
| WO2024112867A1 (en) | 2022-11-23 | 2024-05-30 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2025059037A1 (en) | 2023-09-11 | 2025-03-20 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof |
| WO2025077814A1 (en) * | 2023-10-14 | 2025-04-17 | Shanghai Hansoh Biomedical Company Limited | An antibody-drug conjugate treatment of cancer |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022806A2 (en) * | 2001-09-07 | 2003-03-20 | The Scripps Research Institute | Cbi analogues of cc-1065 and the duocarmycins |
| CN1889978A (zh) * | 2003-12-10 | 2007-01-03 | 米德列斯公司 | 干扰素α抗体及其用途 |
| NZ550934A (en) * | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
| ES2416136T3 (es) * | 2005-09-26 | 2013-07-30 | Medarex, Inc. | Conjugados de anticuerpo-fármaco y su uso |
| SG170080A1 (en) * | 2005-12-08 | 2011-04-29 | Medarex Inc | Human monoclonal antibodies to o8e |
| US9121853B2 (en) * | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
| TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
-
2008
- 2008-11-26 BR BRPI0818963 patent/BRPI0818963A2/pt not_active IP Right Cessation
- 2008-11-26 CL CL2008003526A patent/CL2008003526A1/es unknown
- 2008-11-26 US US12/745,677 patent/US20110085970A1/en not_active Abandoned
- 2008-11-26 EA EA201000910A patent/EA201000910A1/ru unknown
- 2008-11-26 TW TW097145818A patent/TW200938224A/zh unknown
- 2008-11-26 CN CN2008801258530A patent/CN101951959A/zh active Pending
- 2008-11-26 EP EP08858252A patent/EP2224958A2/en not_active Withdrawn
- 2008-11-26 WO PCT/US2008/084923 patent/WO2009073533A2/en active Application Filing
- 2008-11-26 KR KR1020107014485A patent/KR20100093578A/ko not_active Withdrawn
- 2008-11-26 AR ARP080105136A patent/AR069747A1/es unknown
- 2008-11-26 CA CA2706926A patent/CA2706926A1/en not_active Abandoned
- 2008-11-26 JP JP2010536180A patent/JP2011505372A/ja active Pending
- 2008-11-26 MX MX2010005830A patent/MX2010005830A/es not_active Application Discontinuation
- 2008-11-26 AU AU2008334063A patent/AU2008334063A1/en not_active Abandoned
-
2010
- 2010-05-26 IL IL205993A patent/IL205993A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201000910A1 (ru) | 2011-04-29 |
| CN101951959A (zh) | 2011-01-19 |
| IL205993A0 (en) | 2010-11-30 |
| EP2224958A2 (en) | 2010-09-08 |
| US20110085970A1 (en) | 2011-04-14 |
| CL2008003526A1 (es) | 2010-01-11 |
| JP2011505372A (ja) | 2011-02-24 |
| WO2009073533A3 (en) | 2009-11-26 |
| WO2009073533A2 (en) | 2009-06-11 |
| KR20100093578A (ko) | 2010-08-25 |
| AR069747A1 (es) | 2010-02-17 |
| CA2706926A1 (en) | 2009-06-11 |
| MX2010005830A (es) | 2010-09-14 |
| AU2008334063A2 (en) | 2011-01-20 |
| TW200938224A (en) | 2009-09-16 |
| AU2008334063A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0818963A2 (pt) | Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo | |
| BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
| BRPI0906099A2 (pt) | "método de tratamento do câncer em um indivíduo" | |
| BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
| BRPI0909627A2 (pt) | métodos, composições e kits para tratar dores e pruridos | |
| DK2127652T3 (da) | Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| EP2196131A4 (en) | INTRODUCTION SYSTEM IN A SUBJECT | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
| BRPI0911426A2 (pt) | ferramentas terapêuticas e métodos para tratar cegueira | |
| BRPI0818287A2 (pt) | células dendríticas manipuladas e usos para o tratamento do câncer. | |
| BRPI0810806A2 (pt) | Método para tratar uma lesão cutânea em um indivíduo | |
| BRPI0916630A2 (pt) | composições para uso em construção e processo de aplicação das mesmas | |
| BRPI0818056A2 (pt) | Aparelho e métodos para hemodiálise | |
| BRPI0819819A2 (pt) | Preparações, método e kits ùteis para o tratamento de tosse | |
| BRPI0919804A2 (pt) | Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo | |
| BRPI0820212A2 (pt) | Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas | |
| BRPI0913574A2 (pt) | composição de tratamento de acne compreendendo nanoprata e usos | |
| BRPI0718360A2 (pt) | "composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg" | |
| BRPI0822349A2 (pt) | composições e métodos para tratar doenças lisossômicas | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BRPI0820019A2 (pt) | Modo para melhorar aparência da pele usando partículas macroscópias tratadas | |
| BRPI0811059A2 (pt) | combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação | |
| BRPI0918103A2 (pt) | "método para o tratamento da dor em um indivíduo" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/68 (2017.01), A61P 35/00 (2006.01) |